ArticleGlycoconjugate journal2010
Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization.
Article in Glycoconjugate journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Immunotherapeutic effects of recombinant colorectal cancer antigen produced in tomato fruits.Scientific reports · 2022Article
- Current Development of Nano-Drug Delivery to Target Macrophages.Biomedicines · 2022Review
- Novel application of trimethyl chitosan as an adjuvant in vaccine delivery.International journal of nanomedicine · 2018Review
- Nanoparticle-allergen complexes for allergen immunotherapy.International journal of nanomedicine · 2017Review
- Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Protein & cell · 2015Review
- Strategies for intranasal delivery of vaccines.Drug delivery and translational research · 2013Article
- Oligomannose-coated liposome as a novel adjuvant for the induction of cellular immune responses to control disease status.BioMed research international · 2013Review
- Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.Frontiers in microbiology · 2013Article
- Recent progress in mucosal vaccine development: potential and limitations.Nature reviews. Immunology · 2012Review
- The mucosal adjuvant potential of cross-linked dextran microspheres as dry powder.Iranian journal of basic medical sciences · 2012Article
- Liposomes and nanotechnology in drug development: focus on oncotargets.International journal of nanomedicine · 2012Article
- Targeted liposomal drug delivery to monocytes and macrophages.Journal of drug delivery · 2011Article
- SIGNR1 ligation on murine peritoneal macrophages induces IL-12 production through NFkappaB activation.Glycoconjugate journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present study, we investigated the effectiveness of liposomes coated with a neoglycolipid consisting of mannotriose and dipalmitoylphosphatidylcholine (Man3-DPPE) as an adjuvant for induction of mucosal immunity. Immunization of BALB/c mice with ovalbumin (OVA)-encapsulated Man3-DPPE-coated liposomes (oligomannose-coated liposomes; OMLs) by a nasal route produced high levels of OVA-specific IgG and IgA antibodies in serum of immunized mice 1 week after the last nasal immunization, whereas no significant serum antibody responses were observed in mice that received OVA in uncoated liposomes or OVA alone. Seven weeks after the last nasal immunization, nasal challenge with an excess amount of OVA in mice that had received OVA/OMLs led to an anamnestic response to the antigen that resulted in 5- to 10-fold increases of antigen-specific serum IgG and IgA antibodies. Only mice immunized nasally with OML/OVA secreted antigen-specific secretory IgA in nasal washes and produced interferon-gamma secreting cells in nasopharyngeal-associated lymphoreticular tissue. Taken together, these results show that nasal administration of OMLs induces mucosal and systemic immunity that are specific for the entrapped antigen in the liposomes. Thus, liposomes coated with synthetic neoglycolipids might be useful as adjuvants for induction of mucosal immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.